REG - Nuformix PLC - Posting of Annual Report and Notice of AGM

NuformixAnnouncement

15/01/2024 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240115:nRSO7136Za&default-theme=true

RNS Number : 7136Z  Nuformix PLC  15 January 2024

15 January 2024

Nuformix plc

("Nuformix", the "Company" or the "Group")

Posting of Annual Report and Notice of Annual General Meeting ("AGM")

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that
the Annual Financial Report for the 18 months ended 30 September 2023 (the
"Annual Financial Report 2023") and the 2024 Notice of AGM are today being
posted to its shareholders.

A full pdf version of the Annual Financial Report 2023 together with the
Notice of AGM is available for download from the Investor Information section
on the Company's website www.nuformix.com (http://www.nuformix.com/) .

The Annual Financial Report 2023 will be filed with the Registrar of Companies
in due course and copies can be obtained from the Company Secretary, SGH
Company Secretaries Limited, 60 Gracechurch Street, London, EC3V 0HR.

The Annual General Meeting will be held on 19 March 2024 at 2.00 pm at the
offices of Shakespeare Martineau, 6(th) floor, 60 Gracechurch Street, London,
EC3V 0HR.

 

Enquiries:

 

 Nuformix plc
 Dr Daniel Gooding, Executive Director             Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 Bob Pountney (Corporate Broking)                  +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical and Phase
1-ready assets with potential for significant value and early licensing
opportunities.

For more information, please visit www.nuformix.com
(http://www.nuformix.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFLFILLFIELIS